Via News Knowledge File

Pfizer Inc.

organization80% conf.·synced Sep 10, 2026

Pharmaceutical company, collaboration partner on Padcev

sourced metrics

663

relationships

stated objectives

Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Return Ytd

10.3%

Sep 9, 2026reference only

Stock Price

27.78USD

Sep 9, 2026reference only

Market Cap

158336932302USD

Sep 9, 2026reference only

Price 52 Week Low

23.60USD

Sep 9, 2026reference only

Price 52 Week High

29.02USD

Sep 9, 2026reference only

Shares Outstanding

5699673589.0shares

Jul 29, 2026reference only

Eps

-0.04USD_per_share

Jun 28, 2026reference only

Stockholders Equity

85190000000.0USD

Jun 28, 2026reference only

Total Assets

201131000000.0USD

Jun 28, 2026reference only

Net Income

-248000000.0USD

Jun 28, 2026reference only

Revenue

15034000000.0USD

Jun 28, 2026reference only

Cost Of Revenue

4092000000.0USD

Jun 28, 2026reference only

Cash

976000000.0USD

Jun 28, 2026reference only

Total Liabilities

115639000000.0USD

Jun 28, 2026reference only

Operating Cash Flow

2615000000.0USD

Mar 29, 2026reference only

Capex

436000000.0USD

Mar 29, 2026reference only

Stated objectives

Build U.S. manufacturing capacity for Metsera obesity products

source

target: U.S.-produced anti-obesity drugs stated

Full-year revenue forecast

source

target: 59.5-62.5 billion USD by 2026-12-31 00:00:00stated

Revenue CAGR 2025-2030

source

target: 6 by 2030-01-01 00:00:00stated

Obtain global regulatory approvals for PADCEV plus pembrolizumab in cisplatin-eligible MIBC based on EV-304 results

source

stated

Enhance global ADC access through acquisition of Seagen

source

stated

Obtain regulatory approval for HYMPAVZI for treatment of hemophilia A or B with inhibitors from FDA and EMA

source

stated

Complete BASIS KIDS study to evaluate safety and efficacy of HYMPAVZI in children up to <18 years with hemophilia A or B with or without inhibitors

source

stated

Evaluate long-term safety and efficacy of HYMPAVZI in hemophilia patients with or without inhibitors in ongoing open-label long-term extension study

source

stated

Achieve revenues between $59.5 billion and $62.5 billion in 2026

source

target: 59.5-62.5 billion USD by 2026-12-31 00:00:00stated

Achieve adjusted EPS between $2.80 and $3 per share in 2026

source

target: 2.80-3.00 USD by 2026-12-31 00:00:00stated

Relationship graph · 663 connections

Developed by

211

Competes with

acquired by

Covered by

regulates

Partnered with

Employs

Supplies to

acquired by

Medivation, Inc.Biohaven Ltd.Seagen Metsera, Inc.Metsera Seagen

Owns

XTANDI Paxlovid Prevnar Comirnaty Ibrance Eliquis Xeljanz Premarin

develops

PD-1 Resistant Head and Neck Cancer

licensed from

Serina Therapeutics, Inc.

financed by

Partnership for Accelerating Cancer Therapies

Developed by

Atirmociclib ABRYSVO Prevnar Vyndaqel Xeljanz XTANDI Ibrance Padcev Eliquis Mektovi BRAFTOVI Danuglipron

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →